Ceftazidime-avibactam and aztreonam combination for Carbapenem-resistant Enterobacterales bloodstream infections with presumed Metallo-β-lactamase production: a systematic review and meta-analysis

References

• Hu Q, Chen J, Sun S, et al. Mortality-related risk factors and novel antimicrobial regimens for carbapenem-resistant Enterobacteriaceae infections: a systematic review. Infect Drug Resist. 2022 Nov 28;15:6907–6926. doi: 10.2147/IDR.S390635
   PubMed Web of Science ®Google Scholar
• Clancy CJ, Potoski BA, Buehrle D, et al. Estimating the treatment of carbapenem-resistant Enterobacteriaceae infections in the United States using antibiotic prescription data. Open Forum Infect Dis. 2019 Jul 28;6(8):ofz344. doi: 10.1093/ofid/ofz344
   PubMed Web of Science ®Google Scholar
• Wagenlehner F, Lucenteforte E, Pea F, et al. A systematic review on estimated rates of nephrotoxicity and neurotoxicity in patients treated with polymyxins. Clin Microbiol Infect. 2021 May 1;27(5):671–686. doi: 10.1016/j.cmi.2020.12.009
   Web of Science ®Google Scholar
• Mauri C, Maraolo AE, Di Bella S, et al. The revival of aztreonam in combination with avibactam against Metallo-β-Lactamase-Producing Gram-Negatives: a systematic review of in vitro studies and clinical cases. Antibiotics. 2021 Aug 20;10(8):1012. doi: 10.3390/antibiotics10081012
   Google Scholar
• Sterne JA, Hernán MA, Reeves BC, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016 Oct 12;355:i4919. doi: 10.1136/bmj.i4919
   PubMedGoogle Scholar
• Haddaway NR, Page MJ, Pritchard CC, et al. PRISMA2020: an R package and Shiny app for producing PRISMA 2020-compliant flow diagrams, with interactivity for optimised digital transparency and Open Synthesis. Campbell Syst Rev. 2022;18(2):e1230. doi: 10.1002/cl2.1230
   PubMedGoogle Scholar
• Abid MB, Buchan B, Ledeboer N, et al. 1192. Identification of a novel Enterobacter cloacae isolate producing an IMP-13 metallo-β-lactamase. Open Forum Infect Dis. 2018 2018 Nov 26;5(Suppl 1):S360–1. doi: 10.1093/ofid/ofy210.1025
   Google Scholar
• Alghoribi MF, Alqurashi M, Okdah L, et al. Successful treatment of infective endocarditis due to pandrug-resistant Klebsiella pneumoniae with ceftazidime-avibactam and aztreonam. Sci Rep. 2021 May 6;11(1):9684. doi: 10.1038/s41598-021-89255-8
   PubMed Web of Science ®Google Scholar
• Amarsy R, Jacquier H, Munier AL, et al. Outbreak of NDM-1-producing Klebsiella pneumoniae in the intensive care unit during the COVID-19 pandemic: another nightmare. A J Infect Control. 2021 Oct;49(10):1324–1326.
   PubMed Web of Science ®Google Scholar
• Bocanegra-Ibarias P, Camacho-Ortiz A, Garza-González E, et al. Aztreonam plus ceftazidime-avibactam as treatment of NDM-1-producing Klebsiella pneumoniae bacteraemia in a neutropenic patient: Last resort therapy? J Glob Antimicrob Resist. 2020 Dec;23:417–419.
   PubMed Web of Science ®Google Scholar
• Benchetrit L, Mathy V, Armand-Lefevre L, et al. Successful treatment of septic shock due to NDM-1-producing Klebsiella pneumoniae using ceftazidime/avibactam combined with aztreonam in solid organ transplant recipients: report of two cases. Int J Antimicrob Agents. 2020 Jan;55(1):105842.
   PubMed Web of Science ®Google Scholar
• Peri AM, Piazza A, De Zan V, et al. Autochthonous ST405 NDM-5 producing Escherichia coli causing fatal sepsis in Northern Italy. Int J Antimicrob Agents. 2020 May;55(5):105953.
   PubMed Web of Science ®Google Scholar
• Mehdawi F, Al-Ahmadi M, Marhabi H. Effective treatment of ventriculitis with OXA-48 carbapenem-resistant Klebsiella pneumonia, followed by bacteremia with NDM carbapenem-resistant Klebsiella pneumonia-case report. J Infect Public Health. 2020 Feb 1;13(2):343. doi: 10.1016/j.jiph.2020.01.101
   Google Scholar
• Nori P, Szymczak W, Puius Y, et al. Emerging co-pathogens: New Delhi metallo-beta-lactamase producing enterobacterales infections in New York City COVID-19 patients. Int J Antimicrob Agents. 2020 Dec;56(6):106179.
   PubMed Web of Science ®Google Scholar
• Osipov I, Salogub G, Ivanov V, et al. Ceftazidime-avibactam and aztreonam in the treatment of severe infections associated with XDR Klebsiella pneumoniae in neutropenic patients with hematological malignancy: single-center study. Hemasphere. 2020 Jan 1;4:742–743.
   Google Scholar
• Shah PJ, Tran T, Emelogu F, et al. Aztreonam, ceftazidime/avibactam, and colistin combination for the management of carbapenemase-producing klebsiella pneumoniae bacteremia: a case report. J Pharm Pract. 2021 Aug;34(4):653–657.
   PubMed Web of Science ®Google Scholar
• Sieswerda E, van den Brand M, van den Berg RB, et al. Successful rescue treatment of sepsis due to a pandrug-resistant, NDM-producing Klebsiella pneumoniae using aztreonam powder for nebulizer solution as intravenous therapy in combination with ceftazidime/avibactam. J Antimicrob Chemother. 2020 Mar 1;75(3):773–775. doi: 10.1093/jac/dkz495
   PubMed Web of Science ®Google Scholar
• Sempere A, Viñado B, Los-Arcos I, et al. Ceftazidime-avibactam plus aztreonam for the treatment of infections by VIM-type-producing gram-negative bacteria. Antimicrob Agents Chemother. 2022 Oct 18;66(10):e0075122. doi: 10.1128/aac.00751-22
   PubMed Web of Science ®Google Scholar
• Shaw E, Rombauts A, Tubau F, et al. Clinical outcomes after combination treatment with ceftazidime/avibactam and aztreonam for NDM-1/OXA-48/CTX-M-15-producing Klebsiella pneumoniae infection. J Antimicrob Chemother. 2018 Apr 1;73(4):1104–1106. doi: 10.1093/jac/dkx496
   PubMed Web of Science ®Google Scholar
• Hobson CA, Bonacorsi S, Fahd M, et al. Successful treatment of bacteremia due to NDM-1-Producing Morganella morganii with aztreonam and ceftazidime-avibactam combination in a pediatric patient with hematologic malignancy. Antimicrob Agents Chemother. 2019 Jan 29;63(2):e02463–18. doi: 10.1128/AAC.02463-18
   PubMed Web of Science ®Google Scholar
• Davido B, Fellous L, Lawrence C, et al. Ceftazidime-avibactam and aztreonam, an interesting strategy to overcome β-lactam resistance conferred by metallo-β-lactamases in enterobacteriaceae and pseudomonas aeruginosa. Antimicrob Agents Chemother. 2017 Aug 24;61(9):e01008–e01017. doi: 10.1128/AAC.01008-17
   PubMed Web of Science ®Google Scholar
• Cairns KA, Hall V, Martin GE, et al. Treatment of invasive IMP-4 Enterobacter cloacae infection in transplant recipients using ceftazidime/avibactam with aztreonam: a case series and literature review. Transpl Infect Dis. 2021 Apr;23(2):e13510.
   PubMed Web of Science ®Google Scholar
• Perrotta F, Perrini MP. Successful treatment of Klebsiella pneumoniae NDM sepsis and intestinal decolonization with ceftazidime/avibactam plus aztreonam combination in a patient with TTP complicated by SARSCoV-2 nosocomial infection. Medicina (Kaunas). 2021 Apr 28;57(5):424. doi: 10.3390/medicina57050424
   PubMed Web of Science ®Google Scholar
• Yasmin M, Fouts DE, Jacobs MR, et al. Monitoring ceftazidime-avibactam and aztreonam concentrations in the treatment of a bloodstream infection caused by a multidrug-resistant Enterobacter sp. Carrying both Klebsiella pneumoniae carbapenemase-4 and New Delhi metallo-β-lactamase-1. Clin Infect Dis. 2020 Aug 14;71(4):1095–1098. doi: 10.1093/cid/ciz1155
   PubMed Web of Science ®Google Scholar
• Bavaro DF, Belati A, Diella L, et al. Prompt and appropriate antimicrobial therapy improves outcomes of NDM-Producing and KPC-Producing Klebsiella pneumoniae bloodstream infections in patients hospitalized for COVID-19: a comparative retrospective case-series. Antibiot Basel Switz. 2022 Oct 31;11(11):1519. doi: 10.3390/antibiotics11111519
   PubMed Web of Science ®Google Scholar
• Zhang L, Zhen S, Shen Y, et al. Bloodstream infections due to carbapenem-resistant Enterobacteriaceae in hematological patients: assessment of risk factors for mortality and treatment options. Ann Clin Microbiol Antimicrob. 2023 May 18;22(1):41. doi: 10.1186/s12941-023-00586-y
   PubMed Web of Science ®Google Scholar
• Falcone M, Daikos GL, Tiseo G, et al. Efficacy of ceftazidime-avibactam plus aztreonam in patients with bloodstream infections caused by Metallo-β-lactamase-Producing Enterobacterales. Clin Infect Dis. 2021 Jun 1;72(11):1871–1878. doi: 10.1093/cid/ciaa586
   PubMed Web of Science ®Google Scholar
• Prayag PS, Patwardhan SA, Panchakshari S, et al. Ceftazidime-avibactam with or without Aztreonam vs polymyxin-based combination therapy for Carbapenem-resistant Enterobacteriaceae: a retrospective analysis. Indian J Crit Care Med. 2023, Jun;27(6):444–450.
   PubMed Web of Science ®Google Scholar
• Sree RA, Gupta A, Gupta N, et al. Ceftazidime-avibactam alone or in combination with aztreonam versus polymyxins in the management of carbapenem-resistant Klebsiella pneumoniae nosocomial infections (CAPRI study): a retrospective cohort study from South India. Infection. 2023 Sep 11. doi: 10.1007/s15010-023-02094-9
   Web of Science ®Google Scholar
• Falcone M, Tiseo G, Antonelli A, et al. Clinical features and outcomes of bloodstream infections caused by New Delhi metallo-β-lactamase-producing enterobacterales during a regional outbreak. Open Forum Infect Dis. 2020 Feb;7(2):ofaa011.
   PubMed Web of Science ®Google Scholar
• Chatterjee N, Nirwan PK, Srivastava S, et al. Trends in carbapenem resistance in pre-COVID and COVID times in a tertiary care hospital in North India. Ann Clin Microbiol Antimicrob. 2023 Jan 3;22(1):1. doi: 10.1186/s12941-022-00549-9
   PubMed Web of Science ®Google Scholar
• Boyd SE, Livermore DM, Hooper DC, et al. Metallo-β-lactamases: structure, function, epidemiology, treatment options, and the development pipeline. Antimicrob Agents Chemother. 2020 Sep 21;64(10). doi: 10.1128/AAC.00397-20
   Web of Science ®Google Scholar
• Bakthavatchalam YD, Shankar A, Manokaran Y, et al. Can fosfomycin be an alternative therapy for infections caused by E. coli harbouring dual resistance: NDM and four-amino acid insertion in PBP3? JAC Antimicrob Resist. 2023 Mar 4;5(2):dlad016. doi: 10.1093/jacamr/dlad016
   PubMedGoogle Scholar
• Tsuji BT, Pogue JM, Zavascki AP, et al. International consensus guidelines for the optimal use of the polymyxins: endorsed by the American college of clinical pharmacy (ACCP), European society of clinical microbiology and infectious diseases (ESCMID), infectious diseases Society of America (IDSA), international society for anti-infective pharmacology (ISAP), society of critical care medicine (SCCM), and society of infectious diseases pharmacists (SIDP). Pharmacother J Hum Pharmacol Drug Ther. 2019;39(1):10–39.
   Google Scholar
• Vardakas KZ, Falagas ME. Colistin versus polymyxin B for the treatment of patients with multidrug-resistant gram-negative infections: a systematic review and meta-analysis. Int J Antimicrob Agents. 2017 Feb 1;49(2):233–238. doi: 10.1016/j.ijantimicag.2016.07.023
   PubMed Web of Science ®Google Scholar
• Hou SY, Wu D, Feng XH. Polymyxin monotherapy versus polymyxin-based combination therapy against carbapenem-resistant Klebsiella pneumoniae: a systematic review and meta-analysis. J Glob Antimicrob Resist. 2020 Dec;23:197–202. doi: 10.1016/j.jgar.2020.08.024
   PubMed Web of Science ®Google Scholar
• Yang P, Li Y, Wang X, et al. Efficacy and safety of ceftazidime–avibactam versus polymyxins in the treatment of carbapenem-resistant Enterobacteriaceae infection: a systematic review and meta-analysis. BMJ Open. 2023 May 1;13(5):e070491. doi: 10.1136/bmjopen-2022-070491
   PubMed Web of Science ®Google Scholar